Table 1.
Demographics and baseline characteristics by negative hyperselection status
| Overall (N = 733) | Negative hyperselecteda (n = 530) | Gene alteredb (n = 203) | ||||
|---|---|---|---|---|---|---|
| Panitumumab + mFOLFOX6 (n = 368) | Bevacizumab + mFOLFOX6 (n = 365) | Panitumumab + mFOLFOX6 (n = 259) | Bevacizumab + mFOLFOX6 (n = 271) | Panitumumab + mFOLFOX6 (n = 109) | Bevacizumab + mFOLFOX6 (n = 94) | |
| Age category | ||||||
| 20–64 years | 149 (40.5) | 152 (41.6) | 104 (40.2) | 116 (42.8) | 45 (41.3) | 36 (38.3) |
| 65–79 years | 219 (59.5) | 213 (58.4) | 155 (59.8) | 155 (57.2) | 64 (58.7) | 58 (61.7) |
| Sex | ||||||
| Female | 134 (36.4) | 120 (32.9) | 87 (33.6) | 83 (30.6) | 47 (43.1) | 37 (39.4) |
| Male | 234 (63.6) | 245 (67.1) | 172 (66.4) | 188 (69.4) | 62 (56.9) | 57 (60.6) |
| ECOG PS | ||||||
| 0 | 304 (82.6) | 288 (78.9) | 220 (84.9) | 213 (78.6) | 84 (77.1) | 75 (79.8) |
| 1 | 63 (17.1) | 77 (21.1) | 39 (15.1) | 58 (21.4) | 24 (22.0) | 19 (20.2) |
| Primary tumor locationc | ||||||
|
Left sided (n = 554) |
287 (78.0) | 267 (73.2) | 222 (85.7) | 218 (80.4) | 65 (59.6) | 49 (52.1) |
|
Right sidee (n = 169) |
78 (21.2) | 91 (24.9) | 35 (13.5) | 50 (18.5) | 43 (39.4) | 41 (43.6) |
| Number of metastatic organs | ||||||
| 1 | 181 (49.2) | 178 (48.8) | 141 (54.4) | 139 (51.3) | 40 (36.7) | 39 (41.5) |
| ≥2 | 187 (50.8) | 187 (51.2) | 118 (45.6) | 132 (48.7) | 69 (63.3) | 55 (58.5) |
| Metastatic site | ||||||
| Liver | 254 (69.0) | 248 (67.9) | 173 (66.8) | 182 (67.2) | 81 (74.3) | 66 (70.2) |
|
Liver only site of metastases |
96 (26.1) | 102 (27.9) | 73 (28.2) | 78 (28.8) | 23 (21.1) | 24 (25.5) |
| Previous primary tumor resection | 222 (60.3) | 244 (66.8) | 166 (64.1) | 184 (67.9) | 56 (51.4) | 60 (63.8) |
Data are presented as n (%).
a‘Negative hyperselected’ was defined as plasma ctDNA being negative for all prespecified gene alterations, including mutations in BRAF V600E, KRAS, PTEN, EGFR ECD exons 1–16, and NRAS, amplifications of HER2 and MET, and gene fusions of RET, NRTK1 and ALK.
b‘Gene altered’ was defined as detection of any of the following in ctDNA: a mutation in BRAF V600E, KRAS, PTEN, EGFR ECD exons 1–16 and/or NRAS, amplification of HER2 and/or MET, and gene fusion of RET, NRTK1 and/or ALK.
cSome patients had multiple primary lesions on both the left and right sides.
dPrimary tumors originating from the descending colon, sigmoid colon, rectosigmoid and rectum.
ePrimary tumors originating from the right side of the colon, defined as cecum, ascending colon or transverse colon.
ECOG, Eastern Cooperative Oncology Group; PS, performance status.